Latest News

Independent pharmacies are being squeezed on reimbursement while their data quietly fuels billion-dollar decisions. A new pharmacy data economy could flip that script.

The CDC testing pause disrupts diagnostic testing for infectious diseases like rabies and mpox, leaving pharmacists and states scrambling for answers.

Keith Bellovich, DO, explains how SARS-CoV-2–driven inflammation contributes to kidney injury and may reveal previously undiagnosed chronic kidney disease.

Meitheal Pharmaceuticals launches propofol sedation vials for ICU and surgery, cutting waste and dosing errors with 3 single-dose sizes.

Practical strategies to improve clozapine education, monitoring, and utilization while addressing common barriers and safety concerns.

Phase 3 PATCH trial shows estrogen patches cut hot flashes sharply but raise gynecomastia risk.

Myelofibrosis model reveals malignant stem cells reprogram healthy support cells, fueling inflammation and fibrosis.

This article is sponsored by Pacira Pharmaceuticals, Inc.

How pharmacists are uniquely positioned to support athlete health, performance, recovery, and regulatory compliance through medication expertise and interdisciplinary care.

A pharmacist's guide to the most common cancer myths circulating online.

Artificial intelligence, real-world data, and patient voices reshape pharmacovigilance, helping pharmacists spot risks faster and strengthen life cycle drug safety.

Octogenarians with early-stage non–small cell lung cancer (NSCLC) can safely undergo surgery and achieve survival and quality-of-life outcomes comparable to younger patients.

AI is reshaping pharmacy, from catching dangerous drug interactions to personalizing chemotherapy dosing.

New analysis suggests oral semaglutide may offer improved efficacy and tolerability compared with orforglipron, informing treatment selection in an increasingly competitive oral GLP-1 landscape.

Review finds prior authorizations delay neurologic treatment, trigger relapses, and intensify clinician burnout, spurring calls for rapid reform.

Team-based, multidisciplinary care aids personalized treatment, improving coordination across complex therapies, and enhances patient outcomes and long-term quality of life.

The first-in-class triple agonist met all primary and key secondary end points in the TRANSCEND-T2D-1 trial.

The National Association of Boards of Pharmacy (NABP) opens the door to the Occupational English Test (OET) as an alternative English exam for foreign pharmacy graduate certification.

This annual recognition was established by the Hematology/Oncology Pharmacy Association (HOPA) to honor the essential contributions of hematology/oncology pharmacists to the lives of people affected by cancer.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.